Literature DB >> 8700130

Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.

R Ganapathi1, A Constantinou, N Kamath, G Dubyak, D Grabowski, K Krivacic.   

Abstract

Tumor cell resistance to anthracyclines and epipodophyllotoxins can be due to reduced drug accumulation and/or alterations in the activity of topoisomerase II (TOPO II). HL-60 cells selected in 0.05 micrograms/ml doxorubicin (DOX) are 10-fold and > 20-fold resistant to DOX and etoposide (VP-16), respectively. The accumulation of [3H]VP-16 was 2-3-fold lower in the resistant cells (HL-60/DOX 0.05) than in similarly treated parent-sensitive cells (HL-60/S). However, compared with HL-60/S cells, the HL-60/DOX 0.05 cells required > 20-fold higher concentrations of VP-16 to produce equivalent damage to DNA. The reduced formation of VP-16-stabilized DNA cleavable complex in the HL-60/DOX 0.05 cells was not due to differences in the amount of 170-kDa TOPO (alpha) II protein or enzyme catalytic activity between HL-60/S and HL-60/DOX 0.05 cells. Metabolic labeling with [32P]orthophosphoric acid and immunoprecipitation indicated that the level of phosphorylated 170-kDa TOPO II alpha protein in the HL-60-/S cells was 2.2 +/- 0.4-fold higher than that in HL-60/DOX 0.05 cells. Hypophosphorylation (3-fold) of 170-kDa TOPO II protein in HL-60/S cells treated with the calcium chelator 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester produced a > 2-fold reduction in VP-16-induced TOPO II-mediated DNA cleavable complex formation. Two-dimensional mapping of phosphopeptides in complete tryptic digests demonstrated that the reduced phosphorylation of the 170-kDa TOPO II alpha in HL-60/DOX 0.05 cells was due to the hypophosphorylation of at least three phosphopeptides characteristic of HL-60/S cells. Thus, the attenuated ability of TOPO II to form drug-stabilized DNA cleavable complex is related to the phosphorylated state of 170-kDa TOPO II, and in HL-60/DOX 0.05 cells, resistance may be related to hypophosphorylation of three phosphopeptides characteristic of HL-60/S cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700130

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 2.  The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance.

Authors:  Christophe Lotz; Valérie Lamour
Journal:  Cancer Drug Resist       Date:  2020-02-27

3.  Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.

Authors:  M Aoyama; D R Grabowski; G R Dubyak; A I Constantinou; L A Rybicki; R M Bukowski; M K Ganapathi; I D Hickson; R Ganapathi
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

4.  Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.

Authors:  Adrian G Grozav; Kenichi Chikamori; Toshiyuki Kozuki; Dale R Grabowski; Ronald M Bukowski; Belinda Willard; Michael Kinter; Anni H Andersen; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Nucleic Acids Res       Date:  2008-11-29       Impact factor: 16.971

5.  Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.

Authors:  Z Zhou; L A Zwelling; R Ganapathi; E S Kleinerman
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

6.  Post-translational modifications in DNA topoisomerase 2α highlight the role of a eukaryote-specific residue in the ATPase domain.

Authors:  Claire Bedez; Christophe Lotz; Claire Batisse; Arnaud Vanden Broeck; Roland H Stote; Eduardo Howard; Karine Pradeau-Aubreton; Marc Ruff; Valérie Lamour
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

7.  Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma.

Authors:  Zhenhua Hu; Song Gao; Jian Gao; Rui Hou; Chuan Liu; Juanjuan Liu; Beibei Li; Dawo Liu; Shulan Zhang; Bei Lin
Journal:  Int J Mol Sci       Date:  2012-11-23       Impact factor: 5.923

8.  Mechanisms regulating resistance to inhibitors of topoisomerase II.

Authors:  Ram N Ganapathi; Mahrukh K Ganapathi
Journal:  Front Pharmacol       Date:  2013-08-01       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.